The above articles all observed small clinical samples (four patients to dozens of patients), their conclusions about the relationship between TH17/IL-17 and MM prognosis are not uniform, and there was no article that studied bone disease, treatment efficacy, and PFS/overall survival (OS) in the same cohort. The gene discussed is IL17A; the disease is Miyoshi myopathy.